Celebrating 30 years of the MIDSPAN Studies







Phenotype and genotype studies across the generations John Connell

Strengths of population

Parents

- Long term follow up
- High event rate
- Excellent initial phenotyping
 Genetic material

Offspring

- Detailed phenotyping
- Future recording of events

Renfrew Paisley - Mortality



Diabetes mellitus confers increased CV risk in men and women



Diabetes Care, 2005, 28, 1588

Diabetes and hypertension combine to increase CV risk



Adjusted for - Age, BMI, Smoking, Cholesterol, Social status

Impact of weight on CV mortality



Renfrew Paisley Studies

- Complex interplay of cardiovascular risk factors
- Parental generation alone does not allow genetic contribution to be discerned

Development of offspring studies to allow:

- Heritability estimates of key CV phenotypes
- Exploration of familial clustering of disease
- Studies of specific candidate genes
- Focus on specific CV risk factors obesity; Blood pressure; ECG etc

Heritability of key CV and ECG variables

| Phenotype | Heritability | | | | | | |
|------------------------------|------------------|--|--|--|--|--|--|
| BMI | 0.55±0.06* | | | | | | |
| Waist/Hip ratio | 0.39±0.07* | | | | | | |
| Systolic BP | 0.35±0.07 | | | | | | |
| Diastolic BP | 0.53±0.06* | | | | | | |
| ECG Phenotypes | | | | | | | |
| LVM (Rautaharju) gms | $0.55 \pm 0.07*$ | | | | | | |
| Cornell Voltage µV | 0.32 ± 0.06* | | | | | | |
| Sokolow Lyon µV | 0.32 ± 0.06* | | | | | | |
| 12Lead μV | $0.44 \pm 0.06*$ | | | | | | |
| Sokolow Lyon product µV.s | $0.28 \pm 0.06*$ | | | | | | |
| Cornell Voltage product µV.s | $0.28 \pm 0.06*$ | | | | | | |
| 12 Lead product µV.s | 0.36 ± 0.07* | | | | | | |

Good evidence from family approach that several variables are inherited

What are the key genes that lead to this?

Initial candidates studies focus on known pathways

renin/angiotensin/aldosterone system adrenoreceptors signalling pathways involved in CV regulation

Is one form of the gene inherited more often than another in relation to a particular cardiovascular risk factor ?

Studies on G-protein coupling; βadrenoreceptor; angiotensin converting enzyme and aldosterone synthase

| | GNB3 | | B1AR | | ACE | | SF1 | |
|---------------|---------|------|---------|-------|---------|------|---------|------|
| N / familiesª | 610/244 | | 645/245 | | 703/283 | | 610/244 | |
| | Z | р | Z | р | Z | р | Z | р |
| | | | | | | | | |
| Systolic BP | -0.61 | 0.54 | -1.75 | 0.079 | -1.03 | 0.30 | -0.61 | 0.54 |
| Diastolic BP | -0.62 | 0.53 | -1.17 | 0.24 | -0.67 | 0.49 | -0.62 | 0.53 |
| BMI | 0.36 | 0.72 | -1.23 | 0.22 | 0.07 | 0.94 | 0.36 | 0.71 |
| LV mass | 1.3 | 0.19 | -0.72 | 0.47 | -0.09 | 0.93 | 1.3 | 0.19 |
| 12Lead_V | -0.25 | 0.80 | 2.07 | 0.03 | 1.06 | 0.28 | -0.25 | 0.80 |

No individual gene explains variation in measurements in population ? Combinations of genetic factors may be more informative

Future use of resource

- Exploration of other candidate genes
- Better use of family structure and two generation design
- Alternative ways of analysing data use of genetic information to stratify population
- Development of alternative phenotypes eg; focus on central obesity
- Future utilisation of morbidity and mortality data

Summary

- Highly informative and well documented population
- Family structure allows social, environmental and genetic contributions to risk to be identified
- Genetic information needs to be fully exploited; very powerful tool for future research

Acknowledgements

G Watt AF Dominiczak M Upton D Hole S Padmanabhan N Sattar P McFarlane

Chief Scientist Office British Heart Foundation Wellcome Trust Medical Research Council